 Long-term treatment with TDF was safe in HIV/HBV-positive patients on stable care  Tubular proteinuria was significantly higher in women and hypertensive patients  Concomitant ritonavir-boosted lopinavir accelerated eGFR decline in subjects on TDF  HBVDNA load, transaminases and liver stiffness did not predict renal abnormalities  Screening for co-morbidities is needed in sub-Saharan Africa to optimise HIV care
M A N U S C R I P T Introduction
Tenofovir disoproxil fumarate (TDF), the prodrug of the nucleotide analogue reverse transcriptase inhibitor (NRTI) tenofovir, is active against both HIV and HBV. TDF use as part of antiretroviral therapy (ART) carries a risk of proximal tubular dysfunction and declining glomerular filtration rate (GFR), [1] [2] [3] and monitoring of renal function is recommended during treatment. 4, 5 The risk is related to both level and length of TDF exposure and is enhanced by co-administration of pharmacological boosters (e.g., ritonavir), low body weight, and pre-existing chronic kidney disease (CKD). [6] [7] [8] [9] [10] Whilst TDF discontinuation is generally associated with improved renal function, longer exposure and lower GFR at TDF interruption predict a reduced likelihood of GFR recovery. 6 Whilst in North America and Western Europe tenofovir alafenamide fumarate (TAF) provides a recommended alternative formulation with a reduced potential for renal toxicity, 4, 5 TAF is not currently available in resource-limited settings. The World Health Organisation (WHO) recommends TDF as the preferred NRTI for the treatment of HIV and HIV/HBV positive individuals in sub-Saharan Africa (SSA). 11 There are limited data on the occurrence of TDF-related renal adverse events in African populations and only a few reported long-term data. A study from Malawi, South Africa, and Zimbabwe showed similar rates of renal events over 196 weeks in patients randomised to either TDF plus emtricitabine (FTC) or zidovudine (ZDV) plus lamivudine (3TC), each in combination with efavirenz (EFV). 12 A cross-sectional study among HIV-positive subjects who had received ART for a median of 9.3 years in Uganda similarly found no differences in renal function when comparing regimens with and without TDF. 13 Neither study assessed the influence of concomitant use of ritonavir-boosted protease inhibitors (PI/r) or HBV co-infection on renal health. Short-term studies
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reported an increased risk of renal abnormalities with concomitant use of TDF and PI/r in SSA. In South Africa, HIV-1 positive adults on TDF experienced a small but significant decline in eGFR over a median of 13 months, and the decline was larger with concomitant PI use, older age, weight <60 kg, lower baseline eGFR, and CD4 counts <200 cells/mm 3 . 9 In women receiving TDF in combination with either lopinavir/ritonavir (LPV/r) or nevirapine (NVP), renal events were predicted by LPV/r use, baseline HIV-1 RNA load, and baseline eGFR. 7 By 2030, the number of patients requiring second-line ART in SSA is estimated to exceed 4 million, and an increasing number is likely to start therapy with PI/r. 14 At the same time, improved survival among people living with HIV in SSA is unmasking a substantial burden of co-morbidities, including HBV co-infection. 15 Limited data suggest that chronic hepatitis B may worsen renal outcomes. In one study in Zambia, HBV co-infection nearly doubled the odds of a reduced eGFR after adjusting for several factors, and the risk was higher among patients with raised serum transaminases. 16 Whilst the observation suggests a link between HBV disease activity and risk of renal dysfunction, published evidence has not been consistent. 17 The aim of this study was to evaluate the renal function of HIV/HBV co-infected individuals receiving long-term TDF-containing ART in Ghana, integrating cross-sectionally measured tubular proteinuria (TuPr) and prospectively measured eGFR with markers of HIV and HBV status, and analysing the contributing role of PI/r use, hypertension, and diabetes.

Methods
Setting
Eligible HIV/HBV co-infected positive adults (≥18 years) were drawn from the HEPIK (Hepatitis B Infection in Kumasi) prospective observational cohort based at the Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. 18, 19 The cohort was established in 2010. Study visits took place at least once a year when participants underwent clinical assessment and sample collection. The last study visit occurred in November 2015. At study entry, upon detection of HBV co-infection, patients introduced TDF; subsequent management was at the discretion of the treating clinician. Between 2010 and 2015, monitoring for HIV-positive patients at KATH comprised routine measurements of haemoglobin, serum hepatic transaminases, and CD4 cell counts, and sporadic measurements of serum creatinine. Urine dipstick analysis, measurement of blood pressure in asymptomatic patients, and HIV/HBV virological monitoring were not part of routine care. No patient had access to TAF and TAF remains unavailable in Ghana in 2018.
Ethical approval was granted by the Kwame Nkrumah University of Science and Technology, Ghana; all patients gave written informed consent.
Study population
The analysis comprised HEPIK participants who at the last study visit (November 2015) were on stable TDF-containing ART. At this time, patients underwent study-related clinical assessment and sample collection. Adherence to ART was self-reported through an ordinal visual scale graded from 0 to 100%, in 10% increments. Transient elastography was performed using Fibroscan (Ecosens, France) and interpretative cut-offs applied as previously reported. 19, 20 Blood pressure (BP) was measured with a manual sphygmomanometer; abnormal findings were confirmed after the patient
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had rested for ≥20 minutes. Hypertension was graded as 1 (systolic 140-159 or diastolic 90-99 mmHg), 2 (systolic 160-179 or diastolic 100-109 mmHg) and 3 (systolic ≥180 or diastolic ≥110 mmHg). 21 Systolic BP <140 and/or diastolic BP <90 mmHg on antihypertensive therapy was scored as grade 1. Diabetes was defined by glycated haemoglobin (HbA1c) ≥48 mmol/mol or receiving antidiabetic therapy.
Laboratory tests
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), haemoglobin, and CD4 cell counts were measured at the KATH diagnostic laboratory. Laboratory reference ranges are shown in Supplementary Table 1 . Urine samples underwent dipstick analysis for proteinuria, haematuria, and glycosuria with Medi-Test Combi 5S (BHR Pharmaceuticals, Nuneaton, UK), and testing for Schistosoma circulating cathodic antigen (Ag) with the Urine-CCA Cassette test (Rapid Medical Diagnostics, Pretoria, South Africa). 22 Plasma was separated from whole blood in EDTA within one hour of collection and stored immediately at -80 o C. Frozen aliquots of whole EDTA blood, plasma, serum, and urine were shipped to the UK for further testing. In the UK, plasma HIV-1 RNA and HBV DNA were quantified by the RealTime HIV-1 and HBV assays (Abbott Diagnostics, Maidenhead, UK), as previously described. 19 Hepatitis B e antigen (HBeAg) was measured by Architect (Abbott Diagnostics). Creatinine, urinary protein-tocreatinine ratio (uPCR), urinary albumin-to-creatinine ratio (uACR, performed if uPCR >20 mg/mmol), and HbA1c were measured in the accredited diagnostic laboratory of the Royal Liverpool University Hospital, Liverpool, UK. TuPr was defined as uPCR >20 mg/mmol with uACR/uPCR ratio <0.4; 23 significant TuPr was defined by uPCR >30 mg/mmol with uACR/uPCR ratio <0.4. The eGFR was calculated using the CKD epidemiology collaborationderived equation (CKD-EPI); the ethnicity factor was applied (x1.21). 24 TuPr was not included in the analysis of factor associated with eGFR variation and vice-versa, as potential collinearity between the two could not be excluded. This approach resulted in the inclusion of gender and hypertension for TuPr; receipt of LPV/r and CD4 cell count for changes in eGFR; and receipt of LPV/r, duration of HIV diagnosis, and CD4 cell count for RD-eGFR. The robustness of the results was investigated in models that serially added all variables showing p<0.2 in the univariate analysis, including Schistosoma Ag test, liver stiffness, AST, and HbA1c for TuPr; ALT for changes in eGFR; and adherence for RD-eGFR. Haemoglobin was not included in the multivariable model for RD-eGFR as potentially part of the casual pathway of the outcome. The distribution of residuals was assessed for each linear regression, and indicated a good model fit. Performance of dipstick proteinuria (≥0.3 g/l), glycosuria (1.1 mmol/l) and haematuria (≥10 cells/µl) as predictors of TuPr was estimated through a receiver operating characteristic (ROC) analysis. Analyses were performed with STATA v.14.
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Results
Characteristics of the study population
The study population comprised 101 subjects that had received TDF for a median of 4.0 years (IQR 3.8-4.1) ( Table 1) . All subjects were also receiving 3TC and most were receiving EFV (87/101, 86.1%). Ten (9.9%) were on LPV/r, having received the PI/r for a median of 4.4 years (IQR 3.7-5.5). Plasma HIV-1 RNA was detected in 21/101 (20.8%) subjects at median levels of 4.2 log 10 copies/ml (IQR 2.1-5.1). HBV DNA was detected in 15/101 (14.9%) subjects at median levels of 2.7 log 10 IU/ml (IQR 1.7-3.8). Hypertension of any grade was diagnosed in 35/100 (35.0%) subjects. There were 9/101 (8.9%) patients on anti-hypertensive drugs (nifedipine, losartan, bendroflumethiazide) and five of these had elevated blood pressure of grade 1 (n=1), 2 (n=3), or 3 (n=1). Diabetes was diagnosed in 6/101 (5.9%) subjects. There were 3/101 (3.0%) patients on oral hypoglycaemic drugs (metformin, glibenclamide) and one of these had abnormal Hb1Ac levels (80 mmol/mol). The urinary Schistosoma Ag was reactive in 18/101 (17.8%) subjects. None of the participants was taking other regular medications.
Markers of renal health
Tubular proteinuria
The uPCR was median 13 mg/mmol (IQR 13-20) and was >20 mg/mmol in 28/101 (27.7%) patients and >50 mg/mmol in 13/101 (12.9%) patients (Table 2) . Among subjects with uPCR >20mg/mmol, the uACR was median 0.33 mg/mmol (IQR 0.17-0.49). TuPr was diagnosed in 16/101 (15.8%) subjects, including 9/101 (8.9%) with significant TuPr (Supplementary Table 2 ). TuPr was significantly more prevalent in women and patients with
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hypertension and the association was confirmed after adjustment ( Table 3 ). The univariate analysis showed trends for an association between TuPr and higher liver stiffness, higher HbA1c levels, and a positive Schistosoma Ag test. Separate models adjusting for these variables confirmed that gender and hypertension were each independently associated with TuPr (Supplementary Table 3 ).
Changes in eGFR over time
At the last study visit, the eGFR was median 103 ml/min/1.73m 2 (IQR 92-116) and was <90 ml/min in 22/101 (21.8%) subjects, including 4/101 (4.0%) subjects with levels <30 ml/min ( Table 2 ). The analysis of changes in eGFR over time comprised 90 subjects with data from three time points (T0, T1, T2) and seven subjects with data from two time points (T0 and T2). T0 occurred prior to TDF introduction (median -0.2 months; IQR -2.2, -0.1), whereas T1 and T2 occurred a median of 8.1 months (IQR 5.9-10.9) and 4.0 years (IQR 3.8-4.1) after TDF introduction, respectively. By univariate linear regression analysis, receiving LPV/r at T2 was associated with a larger eGFR decline, and the association persisted after adjusting for CD4 cell counts ( Table 4 ). Of the total population on LPV/r, four subjects had started LPV/r prior to T0, five between T0 and T1, and one between T1 and T2.
The univariate analysis indicated a trend for an association between changes in eGFR and ALT levels. A separate model adjusting for CD4 cell counts and ALT levels confirmed the independent association between LPV/r and eGFR decline (coefficient -3.31; 95% CI -5.87,-0.75; p=0.01); no other independent predictors were identified (not shown).
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A diagnosis of RD-eGFR was made in 21/97 (21.6%) subjects. Patients with RD-eGFR were more likely to be receiving LPV/r, and the association persisted after adjustment ( Table 3) . Among the four subjects with eGFR <60 ml/min at T2, two had experienced RD-eGFR, whereas the other two had a low eGFR at T0. In the main logistic regression model, receiving LPV/r independently increased the risk of RD-eGFR after adjusting for duration of HIV diagnosis. A separate model also adjusting for adherence confirmed the findings with an odds ratio (OR) of 5.27 (95% CI 1.13-24.5; p=0.03) (not shown).
Relationship between TuPr, eGFR, and urinary dipstick results
Median eGFR and prevalence of eGFR <90 ml/min were similar in subjects with and without TuPr ( Table 2) . Changes in eGFR were slightly greater in subjects with TuPr (median -2.4 ml/min/year) than in those without TuPr (median -1.7 ml/min/year). As a result, a diagnosis of RD-eGFR was made in a slightly larger proportion of subjects with TuPr (4/16; 25.0%) than in those without TuPr (17/85; 20.0%). Patients with TuPr showed increased prevalence of dipstick haematuria, and to a lesser extent increased prevalence of dipstick proteinuria. The ROC analysis indicated poor agreement between TuPr and dipstick proteinuria, glycosuria and haematuria, with an area under the curve (r) of 0.56, 0.55, and 0.61, respectively ( Supplementary Figure 1) . A diagnosis of RD-eGFR was not associated with clear dipstick patterns, although prevalence of glycosuria was higher than in patients without RD-eGFR. A detailed summary of urinary dipstick results in relation to a diagnosis of TuPr, RD-GFR, hypertension, diabetes, or Schistosoma Ag positivity is presented in Supplementary Table 4 .
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Discussion
Among HIV/HBV co-infected subjects on long-term TDF-containing ART prevalence of TuPr was 15.8%, and the risk was highest among women and those with hypertension. There was an overall modest eGFR decline over time (1.8 ml/min per year of TDF), but 21.6% of participants experienced a more pronounced decline (≥5 ml/min per year). Despite the small number of patients on LPV/r, a strong association was detected between a larger eGFR decline and receiving LPV/r. There was limited overlap between TuPr and RD-eGFR, pointing at the different impact of promoting factors. In addition, there was no clear evidence of an effect of HBV disease activity on the two renal markers, as expressed by HBV DNA load, HBeAg status, transaminase levels, and liver stiffness. Urinary dipstick failed to accurately predict TuPr, although was able to point to important co-morbidities (i.e., proteinuria with hypertension and schistosomiasis, glycosuria with hypertension and diabetes).
Previous studies conducted predominantly in HIV-positive patients of white ethnicity reported tubular dysfunction in 7-22% of subjects receiving TDF-containing ART for up to nearly five years. [25] [26] [27] [28] Prevalence of TuPr in the Kumasi cohort after a median of four years of TDF was close to the upper limit of the reported range, and hypertension increased the risk by over four-fold. There is a growing burden of hypertension across West Africa, and whilst the determinants remain to be fully established, the attributable mortality is estimated to have increased by over 100% between 1990 and 2015. 29 The prevalence of diagnosed hypertension can reach 54% in the general population 30 and hypertension is estimated to account for 32% of all cases of CKD in Ghana. 31 A third of patients in our study had hypertension, although only a few reported a previous diagnosis and fewer still were receiving anti-hypertensive medication. A similar high rate of untreated hypertension among HIV-positive patients has been reported from
other regions of SSA. 32 While we found no evidence of related clinical events d among patients still attending for care, the findings clearly highlight the urgent need to introduce routine blood pressure screening in African HIV care settings.
There was also a strong association between TuPr and female gender, although the large confidence interval prevented an accurate estimation of the magnitude of the risk. Previous studies investigating factors associated with tubulopathy in HIV-positive subjects did not identify an effect of gender but included predominantly Caucasian males. 26, 33, 34 An association between female gender and risk of renal disease has been described, which may reflect the influence of sex hormones on several biological processes involved in kidney injury. 35 It could also be speculated that greater adherence or lower body weight among women may have increased TDF exposure relative to men, increasing the risk of tubulopathy. In SSA, women have been reported to have greater adherence to ART than men 36 and a similar trend was present in our cohort, with adherence rates ≥90% by visual scale reported in 91% of women and 79% of men respectively. The BMI however did not show an association with renal abnormalities, being higher in women than in men (24.2 vs. 21.4 km/m 2 ). Data from bigger cohorts are needed to confirm the role of gender in increasing the risk of tubular proteinuria among HIV-positive people on TDF-containing ART.
A previous study of the general population in the same region of Ghana showed that approximately 2% of adults (mean age 55 years) had an eGFR <60 ml/min. 37 This compares with a prevalence of 4% in our study, where the mean age was 45 years, suggesting a greater burden of renal disease. It should be noted that after a median of four years of exposure to TDF, there was only a modest decline in eGFR, which is in line with the reported
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overall good safety profile of TDF. 38 Importantly, and consistent with previous data, 7, 9 there was evidence that the eGFR decline was greater in patients receiving LPV/r. Concomitant treatment with LPV/r may indirectly increase the risk of renal damage by boosting TDF exposure through reduced excretion or increased reabsorption, whilst other PIs may have a more direct nephrotoxic potential. 39 As the impact of concomitant PI may differ by type, it will be important to monitor the relative impact of atazanavir and darunavir, which are becoming available across SSA. 40 CKD is estimated to have an overall prevalence of 14% across populations of SSA, although attention has been drawn to the poor quality of the data and the need for more information using validated measures of kidney function. 30 In addition to the direct effect of poorly controlled HIV, rising prevalence of CKD in SSA may be fuelled by increasing urbanisation, dietary changes, and growing rates of tobacco consumption, obesity, diabetes and hypertension acting on a background of longer life-expectancy 30 and genetic predisposition to renal disease. 41 There are limited data suggesting that diabetes is a significant contributor to renal disease in HIV-positive African cohorts. 30, 42 Although numbers were small, in our study there appeared to be a role for diabetes as a determinant of renal abnormalities, again pointing at the importance of screening for co-morbidities in HIV care settings.
A previous study suggested a role for HBV co-infection in increasing the risk of renal disease in Zambian HIV-positive adults. 16 Reassuringly, we detected no indication that HBV status increased the risk of renal function abnormalities. Among infectious co-morbidities with a potential impact on renal health, high rates of Schistosoma infection may play a role in Ghana. In Kumasi, prevalence rates of 21% have been described among hospital
attendees, although varying considerably according to likelihood of exposure to contaminated water. 43 S. haematobium, which causes chronic infection of the urinary tract tends to prevail over S. mansoni, 44 although immunological-mediated impairment of glomerular and tubular function has also been associated with infection by S. mansoni. 45 Our data documented a reactive CCA-test in 17.8% of subjects, which suggest a high burden of infection. A reactive CCA-test was often accompanied by dipstick proteinuria and haematuria, and carried a 2.5-fold increase in the odds of tubular proteinuria. Data are needed to ascertain the impact of specific Schistosoma treatment on urinary findings.
There are limitations of this study. As it is often the case with cohorts in SSA, we observed a significant loss to follow-up (26%) and a documented mortality rate of at least 8% over five years. While some subjects may have moved to a different part of the country, most loss is believed to reflect 
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